The new SARCLISA J-code J9227 is now available, effective October 1, 2020, to be used for reimbursement claims. Refer to the Billing and Coding Guide on the Resources page for additional details. MAT-US-2018558-v1.0-08/2020

MECHANISM OF ACTION

SARCLISA Is a Multimodal Anti-CD38 mAb

Targeted binding to a specific epitope
induces distinct antitumor activity1-3

ADCC=antibody-dependent cell-mediated cytotoxicity; ADCP=antibody-dependent cellular phagocytosis;
CDC=complement-dependent cytotoxicity; mAb=monoclonal antibody; NK=natural killer.

Back to topTop CareASSIST Patient Support

References: 1. SARCLISA [prescribing information]. Bridgewater, NJ: sanofi-aventis U.S. LLC. 2. Martin TG, Corzo K, Chiron M, et al. Therapeutic opportunities with pharmacological inhibition of CD38 with isatuximab. Cells. 2019;8(12):E1522. doi:10.3390/cells8121522. 3. Attal M, Richardson PG, Rajkumar SV, et al; on behalf of the ICARIA-MM study group. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019;394(10214):2096-2107.